As the Ritonavir case demonstrated, the correlation between the structures of solid API phases in pharmaceutical formulations and their lattice free energies and therefore solubilities is of crucial importance in drug delivery. In parallel with the obvious experimental approach to polymorph screening and structure determination, we have carried out commercial computational polymorph screens for the pharmaceutical industry for more than a decade now. This experience puts us in a unique position to report on not just a case study, but on what the statistics over 25 such polymorph screens can tell us.
